Bilateral acute iris transillumination syndrome following COVID-19 infection and moxifloxacin use

Clin Exp Optom. 2024 Sep;107(7):764-766. doi: 10.1080/08164622.2023.2241033. Epub 2023 Sep 6.

Authors

Katerina Lazari¹, Sofia Androudi², Efthymios Dardiotis³, Evangelia E Tsironi², Eleni Papageorgiou¹

Affiliations

¹ Department of Ophthalmology, University Hospital of Larissa, Larissa, Greece.
² Department of Ophthalmology, University Hospital of Larissa, University of Thessaly, Larissa, Greece.
³ Department of Neurology, University Hospital of Larissa, University of Thessaly, Larissa, Greece.

PMID: 37674269
DOI: 10.1080/08164622.2023.2241033

No abstract available

Keywords: Bilateral acute iris transillumination; COVID-19; moxifloxacin; pigment dispersion.

Publication types

Case Reports

MeSH terms

Acute Disease
Anti-Bacterial Agents / therapeutic use
COVID-19 Drug Treatment
COVID-19* / complications
Female
Humans
Iris Diseases* / diagnosis
Male
Middle Aged
Moxifloxacin* / therapeutic use
SARS-CoV-2*
Syndrome

Substances

Moxifloxacin
Anti-Bacterial Agents